News Focus
News Focus
Followers 2
Posts 1107
Boards Moderated 0
Alias Born 11/10/2006

Re: None

Wednesday, 03/12/2008 9:37:31 AM

Wednesday, March 12, 2008 9:37:31 AM

Post# of 8474
Does this news have any implications for Proellex? Wouldn't Daiichi be better off buying our drug?


Posted by: DewDiligence
In reply to: None Date:3/12/2008 6:28:00 AM
Post #of 60265

FDA Rejects Daiichi Sankyo Drug for Uterine Bleeding

[This is yet another case where the FDA contravened the recommendation from an advisory panel.]

http://www.reuters.com/article/marketsNews/idINT24684720080312

>>
Wed Mar 12, 2008 3:48am EDT

TOKYO, March 12 (Reuters) - U.S. regulators have rejected Daiichi Sankyo Co Ltd's injectable anaemia drug Injectafer for the broad treatment of uterine bleeding and in a surprise move also knocked it back for a narrower use.

The Japanese drug maker, which licensed rights to the drug from Swiss healthcare provider Galenica, said it had received a "non-approvable" letter from the U.S. Food and Drug Administration.

An advisory panel to the FDA had voted in February against recommending broad use of the drug but said the benefits outweighed the risks for women who could not tolerate oral iron or had an unsatisfactory response to it.

Galenica shares soared last month after it appeared likely to receive approval for the narrower indication.

The FDA is not bound by the panel's recommendations but takes the advice into consideration.

The FDA asked for additional trials and safety data and Daiichi Sankyo said in a statement it would continue to develop the drug.
<<


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RPRX News